USA – Vicinitas Therapeutics, a South San Francisco, CA-based biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, launched with $65m in Series A financing.
The round was co-led by a16z and Deerfield Management, with participation from Droia Ventures, GV, The Mark Foundation for Cancer Research and the Berkeley Catalyst Fund. Vicinitas Therapeutics is a spin-out company that resulted from the Deubiquitinase Targeting Chimera (, which was developed through an academic-industry research collaboration between the Novartis Institutes for BioMedical Research and researchers at the University of California, Berkeley. Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company’s mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. It was spun out of technology (the DUBTAC platform) that was developed through an academic-industry collaboration between Novartis Institutes for BioMedical Research and researchers at the University of California, Berkeley.Vicinitas Therapeutics has exclusively licensed the DUBTAC platform and aims to become the leading company in targeted protein stabilization by developing next-generation disease therapies against an entire class of previously inaccessible aberrantly degraded proteins. The company is initially focused on developing therapies in cancer and monogenic diseases.The leadership team includes:The board of directors includes:The scientific advisory board include:28/07/2022
